Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA (Mer-targeting)
- Development stage
- Preclinical
- Lead developer
- University of Colorado
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
shRNA (Mer-targeting) refers to short hairpin RNA molecules designed to specifically silence the expression of the Mer receptor tyrosine kinase (MERTK). MERTK is a member of the TAM (Tyro3, Axl, Mer) family of receptor tyrosine kinases and is frequently overexpressed or activated in various malignancies, including metastatic melanoma, where it promotes cell survival, migration, and chemoresistance. By utilizing the RNA interference (RNAi) pathway, these shRNA molecules trigger the sequence-specific degradation of MERTK mRNA, leading to reduced protein levels and the subsequent inhibition of downstream oncogenic signaling pathways such as MAPK/ERK, PI3K/Akt, and Jak/STAT. Preclinical research has demonstrated that Mer-targeting shRNA can significantly reduce colony formation and diminish tumor volume in human melanoma xenograft models, providing a rationale for the development of Mer-targeted therapeutic strategies.
- Other names
- Mer-targeting shRNAMERTK-targeting shRNAshRNA-Mer
02
Targets
MERTK (MER proto-oncogene, tyrosine kinase)
Beyond the preview
Go deeper on shRNA (Mer-targeting).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shRNA (Mer-targeting).